摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(2-ethyl-5,6,7,8-tetrahydroquinolin-4-yl)oxymethyl]phenylboronic acid | 143805-55-4

中文名称
——
中文别名
——
英文名称
4-[(2-ethyl-5,6,7,8-tetrahydroquinolin-4-yl)oxymethyl]phenylboronic acid
英文别名
[4-[(2-ethyl-5,6,7,8-tetrahydroquinolin-4-yl)oxymethyl]phenyl]boronic acid
4-[(2-ethyl-5,6,7,8-tetrahydroquinolin-4-yl)oxymethyl]phenylboronic acid化学式
CAS
143805-55-4
化学式
C18H22BNO3
mdl
——
分子量
311.189
InChiKey
QZNAIUCIJVDCNR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    520.0±60.0 °C(Predicted)
  • 密度:
    1.19±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.78
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    62.6
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Heterocyclic boron compounds as intermediates for angiotensin II
    申请人:Imperial Chemical Industries PLC
    公开号:US05245035A1
    公开(公告)日:1993-09-14
    The invention concerns novel boron compounds of the formula IV, in which Q, Y.sup.1, G.sup.1 and G.sup.2 have the various meanings defined herein, and their acid and base addition salts. The said compounds are useful in the manufacture of certain quinoline, pyridine and imidazole derivatives which have angiotensin II inhibitory activity. The invention also provides novel processes for the production of the quinoline, pyridine and imidazole derivatives. ##STR1##
    该发明涉及公式IV的新型硼化合物,其中Q、Y.sup.1、G.sup.1和G.sup.2具有本文定义的各种含义,以及它们的酸盐和碱盐。所述化合物在制造具有抑制血管紧张素II活性的某些喹诺啉、吡啶和咪唑衍生物方面具有用途。该发明还提供了制备喹诺啉、吡啶和咪唑衍生物的新工艺。
  • Angiotension II antagonizing pyridine derivatives
    申请人:Imperial Chemical Industries PLC
    公开号:US05198439A1
    公开(公告)日:1993-03-30
    The invention concerns pharmaceutically useful novel compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
    本发明涉及式I的新型药物化合物,其中R.sup.1,R.sup.2,R.sup.3,R.sup.4,R.sup.5,R.sup.6,R.sup.7,X和Z具有本文中定义的各种含义,以及它们的非毒性盐和含有它们的药物组成物。这些新型化合物在治疗高血压和充血性心力衰竭等疾病方面具有价值。本发明还涉及制造新型化合物的过程以及化合物在医疗治疗中的使用。
  • Chemical process for making angiotesin II antagonist compounds
    申请人:Imperial Chemical Industries PLC
    公开号:US05294716A1
    公开(公告)日:1994-03-15
    The invention provides a novel chemical process for the manufacture of quinoline, pyridine and imidazole derivatives of the formula IV wherein Q, Y.sup.1 and Y.sup.2 have the various meanings defined herein, and their non-toxic salts, which are angiotensin II inhibitors. The process involves the removal of an electron-deficient phenyl group or a pyridyl or pyrimidyl group from a compound of the formula VI as defined herein.
    该发明提供了一种新颖的化学过程,用于制造公式IV中Q、Y.sup.1和Y.sup.2具有本文定义的各种含义的喹啉、吡啶和咪唑衍生物,以及它们的无毒盐,这些物质是血管紧张素II抑制剂。该过程涉及从本文定义的公式VI中去除一个电子亏缺的苯基或吡啶基或嘧啶基。
  • Angiotensin II antagonizers which are condensed pyridine derivatives
    申请人:Imperial Chemical Industries PLC
    公开号:US05130318A1
    公开(公告)日:1992-07-14
    The invention concerns pharmaceutically useful novel compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
    这项发明涉及具有以下结构的药用新化合物(公式I),其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、X和Z具有此处定义的各种含义,以及它们的无毒盐和含有它们的药物组合物。这些新化合物对于治疗高血压和充血性心力衰竭等疾病具有价值。该发明还涉及制造这些新化合物的过程以及将这些化合物用于医疗治疗的用途。
查看更多